Association of neovascular age-related macular degeneration with migraine
Scientific Reports, 2022 Patients with early onset vascular pathology have been reported to manifest neovascular age-related macular degeneration (AMD). While the blood vessels involved in pathogenesis of migraine remains controversial, it is generally accepted that a major ...
Tung-Mei Kuang +4 more
doaj +1 more source
, 2020 Producción CientíficaABSTRACT: BACKGROUND: The aim of this study was to determine the intra-session repeatability and inter-examiner reproducibility of the colour perimetry technique when assessing in vivo macular pigment optical density in age-related ...
Coco Martín, Rosa María +4 more
core +2 more sources
Quantitative Autofluorescence in Non-Neovascular Age Related Macular Degeneration
Biomedicines, 2023 Quantitative autofluorescence (qAF8) level is a presumed surrogate marker of lipofuscin content in the retina. We investigated the changes in the qAF8 levels in non-neovascular AMD. In this prospective cohort study, Caucasians aged ≥50 years with varying
Shruti Chandra +7 more
doaj +1 more source
Treatment as required versus regular monthly treatment in the management of neovascular age-related macular degeneration: a systematic review and meta-analysis [PDF]
, 2015 Background: To investigate whether treatment as required ‘pro re nata’ (PRN) versus regular monthly treatment regimens lead to differences in outcomes in neovascular age-related macular degeneration (nAMD).
Agostini, Hansjuergen +7 more
core +3 more sources
Health State Utility Values for Age-Related Macular Degeneration: Review and Advice [PDF]
, 2016 Health state utility values are a major source of uncertainty in economic evaluations of interventions for age-related macular degeneration (AMD). This review identifies and critiques published utility values and methods for eliciting de novo utility ...
Butt, T, Rubin, G, Tufail, A
core +1 more source
New Therapies of Neovascular AMD beyond Anti-VEGF Injections
Vision, 2018 Neovascular age-related macular degeneration is a leading cause of vision loss among the aging population. The current standard of care to treat neovascular age-related macular degeneration is inhibiting vascular endothelial growth factor (VEGF) through ...
Greggory M. Gahn, Arshad M. Khanani
doaj +1 more source
Complement C3 variant and the risk of age-related macular degeneration [PDF]
, 2007 Background: Age-related macular degeneration is the most common cause of blindness in Western populations. Susceptibility is influenced by age and by genetic and environmental factors.
Armbrecht, AM +16 more
core +1 more source
Ranibizumab in neovascular age-related macular degeneration
Clinical Interventions in Aging, 2006 Neovascular age-related macular degeneration (AMD) is a visually devastating condition resulting from choroidal neovascularization and secondary photoreceptor loss. Ranibizumab and bevacizumab are medications that target vascular endothelial growth factor (VEGF).
T Eng, Kenneth, Peter J, Kertes
openaire +2 more sources
Intravitreal conbercept injection for neovascular age-related macular degeneration [PDF]
International Journal of Ophthalmology, 2019 AIM: To evaluate the efficacy and safety of intravitreal injection of conbercept in patients with neovascular age-related macular degeneration (AMD). METHODS: Retrospective review of 66 eyes of 63 patients with neovascular AMD. All patients received 0.5
Bing-Hui Wu +4 more
doaj +1 more source
Evaluation of Flowmetry Indicators in Patients with a Wet AMD Form during Antiangiogenic Therapy
Oftalʹmologiâ, 2019 Purpose: to assess the effect of aflibercept (Eylea; “Regeneron”, USA) intravitreal injections on ocular blood flow and intraocular pressure parameters in patients with neovascular form of age-related macular degeneration (wet AMD).
N. Yu. Yousef +5 more
doaj +1 more source